Incyte Corporation

1801 Augustine Rd
Wilmington, DE 19803

Incyte Corporation News

INCYTE CORPORATION: Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY)today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). Read More »

INCYTE CORPORATION: FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S.Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT® (baricitinib), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies. Read More »

Incyte, Merck launch studies examining combination of cancer drugs

Incyte Corp. and Merck have initiated a clinical development program that will examine the possibility of combining epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). Read More »